secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001558370-24-011984
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024
--------------------------------------------------------------------------------

- 45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).
- No significant issues; accelerated start to MAD Part 2 dosing began June 2024.
- Top-line SAD data expected Q3 2024; MAD top-line data Q1 2025.
- Pre-clinical data showed superior weight loss vs semaglutide and survodutide, comparable to tirzepatide.
- Part 3 IND update planned; first patient dosing Q3 2025, interim data mid-2026, top-line H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/0001558370-24-011984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/nrbo-20240813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer